Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47453
Title: Inconsistencies of the Disease Activity Assessment Tools for Psoriatic Arthritis: Challenges to Rheumatologists
Authors: Gezer H.H.
Duruöz M.T.
Nas K.
Kılıç E.
Sargın B.
Kasman S.A.
Alkan H.
Şahin, Nilay
Cengiz, Gizem
Cüzdan, Nihan
Gezer, İlknur Albayrak
Keskin, Dilek
Mülkoğlu, Cevriye
Reşorlu, Hatice
Sunar, İsmihan
Bal, Ajda
Küçükakkaş, Okan
Yurdakul, Ozan Volkan
Melikoğlu, Meltem Alkan
Baykul, Merve
Ayhan, Fikriye Figen
Bodur, Hatice
Çalış, Mustafa
Çapkın, Erhan
Devrimsel, Gül
Gök, Kevser
Hizmetli, Sami
Kamanlı, Ayhan
Keskin, Yaşar
Ecesoy, Hilal
Kutluk, Öznur
Şen, Nesrin
Şendur, Ömer Faruk
Tekeoğlu, İbrahim
Tolu, Sena
Toprak, Murat
Tuncer, Tiraje
Keywords: Composite index
Disease activity
Psoriatic arthritis
Remission
adult
anxiety
Article
clinical assessment
clinical assessment tool
controlled study
dactylitis
DAS28
depression
disease activity
Disease Activity in Psoriatic Arthritis
disease activity score
disease duration
diverse activity scale
enthesitis
fatigue
female
Fibromyalgia Rapid Screening Tool
Health Assessment Questionnaire
Hospital Anxiety and Depression Scale
human
joint swelling
low disease activity
major clinical study
male
middle aged
minimal disease activity
patient-reported outcome
physical examination
psoriatic arthritis
rate of remission
remission
rheumatologist
very low disease activity
visual analog scale
enthesopathy
psoriatic arthritis
severity of illness index
treatment outcome
antirheumatic agent
prostate specific antigen
Antirheumatic Agents
Arthritis, Psoriatic
Enthesopathy
Female
Humans
Male
Prostate-Specific Antigen
Remission Induction
Rheumatologists
Severity of Illness Index
Treatment Outcome
Publisher: Elsevier Masson s.r.l.
Abstract: Objective: Currently, concerning the evaluation of psoriatic arthritis (PsA), there is no agreement on a standardized composite index for disease activity that includes all relevant domains. The present study sought to assess the rates of remission (REM)/low disease activity (LDA) and disease states [minimal disease activity (MDA), very low disease activity (VLDA)] as defined by diverse activity scales (DAPSA, DAS28-ESR) in an attempt to display discrepancies across these assessment tools for peripheral PsA. Methods: The study involved 758 patients (496 females, 262 males; mean age 47,1 years) with peripheral PsA who were registered to the Turkish League Against Rheumatism (TLAR) Network. The patients were assessed using the DAS28-ESR, DAPSA, MDA, and VLDA. The overall yield of each scale was assessed in identifying REM and LDA. The presence or absence of swollen joints was separately analysed. Results: The median disease duration was 4 years (range 0-44 years). According to DAPSA and DAS28-ESR, REM was achieved in 6.9% and 19.5% of the patients, respectively. The rates of MDA and VLDA were 16% and 2.9%, respectively. Despite the absence of swollen joints, a significant portion of patients were not considered to be in REM (296 (39.1%) patients with DAS28-ESR, 364 (48%) with DAPSA, and 394 (52%) with VLDA). Conclusion: Patients with peripheral PsA may be assigned to diverse disease activity levels when assessed with the DAS28-ESR, DAPSA, MDA and VLDA, which would inevitably have clinical implications. In patients with PsA a holistic approach seems to be necessary which includes other domains apart from joint involvement, such as skin involvement, enthesitis, spinal involvement, and patient-reported outcomes. © 2021 Société française de rhumatologie
URI: https://doi.org/10.1016/j.jbspin.2021.105296
https://hdl.handle.net/11499/47453
ISSN: 1297-319X
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu

Show full item record



CORE Recommender

SCOPUSTM   
Citations

9
checked on Jun 29, 2024

Page view(s)

40
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.